Clinical Cancer Research, Vol 2, Issue 10 1757-1765, Copyright © 1996 by American Association for Cancer Research

ARTICLES

Quantitation of somatostatin receptor type 2 gene expression in neuroblastoma cell lines and primary tumors using competitive reverse transcription-polymerase chain reaction

R Sestini, C Orlando, A Peri, C Tricarico, M Pazzagli, M Serio, A Pagani, G Bussolati, S Granchi and M Maggi
Clinical Biochemistry, Endocrinology, and Andrology Units, Department of Clinical Physiopathology, University of Florence viale Pieraccini 6, 50139 Florence, Italy.

We previously reported the presence of somatostatin (SS-14)-binding sites in a wide panel of human neuroblastoma (NB) tumor cell lines. Given that the adrenal gland and its relative embryonal and adult tumors express an abundance of mRNA for somatostatin receptor type 2 (sst2) mRNA, we studied the quantitative expression of sst2 in 6 NB cell lines and 15 primary tumors using competitive reverse transcription (RT)-PCR. This method uses an insertion mutant of the target gene as a competitor for the RT-PCR reaction, thus allowing exact quantitation of sst2 mRNA abundance. We found expression of specific transcripts for sst2 in all of the NB cell lines and tumors investigated (range, 9 x 10(5)-4 x 10(9) molecules/microg RNA). In NB cells, the expression of sst2 was highly correlated with SS-14-binding sites (R = 0.93). In primary tumors, sst2 was positively related to the expression of the neuroendocrine marker secretogranin II (P < 0.05) and negatively related to N-myc amplification (a poor prognostic factor, P < 0.005) and metastatic dissemination (P < 0.05). In addition, Kaplan-Meier curves indicate that sst2 expression is positively related to survival (P = 0.01). In a patient with stage IVs disease (a spontaneously regressing form), we found the highest sst2 expression (4 x 10(9) molecules/microgram RNA), a value relatively similar to that of normal adrenal. In conclusion, these data indicate that quantitation of sst2, as assessed with competitive RT-PCR, could represent a new prognostic tool in the neuroendocrine tumor NB. Since sst2 recognizes octreotide with high affinity, these findings could also have both diagnostic and therapeutic value.

This article has been cited by other articles:

				S. V. de Sa, M. L. Correa-Giannella, M. C. Machado, J. J. S de Souza, M. A. A. Pereira, R. A. Patzina, S. A. C. Siqueira, M. C. C. Machado, and D. Giannella-Neto Somatostatin receptor subtype 5 (SSTR5) mRNA expression is related to histopathological features of cell proliferation in insulinomas. Endocr. Relat. Cancer, March 1, 2006; 13(1): 69 - 78. [Abstract] [Full Text] [PDF]

				J. C. Reubi Peptide Receptors as Molecular Targets for Cancer Diagnosis and Therapy Endocr. Rev., August 1, 2003; 24(4): 389 - 427. [Abstract] [Full Text] [PDF]

				N. Ardjomand, N. Ardjomand, G. Schaffler, H. Radner, and Y. El-Shabrawi Expression of Somatostatin Receptors in Uveal Melanomas Invest. Ophthalmol. Vis. Sci., March 1, 2003; 44(3): 980 - 987. [Abstract] [Full Text] [PDF]

				C. C. Raggi, M. Maggi, D. Renzi, A. Calabrò, M. L. Bagnoni, P. Scaruffi, G. P. Tonini, M. Pazzagli, B. De Bernardi, G. Bernini, et al. Quantitative Determination of sst2 Gene Expression in Neuroblastoma Tumor Predicts Patient Outcome J. Clin. Endocrinol. Metab., October 1, 2000; 85(10): 3866 - 3873. [Abstract] [Full Text]

				J. C. Reubi, B. Waser, Q. Liu, J. A. Laissue, and A. Schonbrunn Subcellular Distribution of Somatostatin sst2A Receptors in Human Tumors of the Nervous and Neuroendocrine Systems: Membranous Versus Intracellular Location J. Clin. Endocrinol. Metab., October 1, 2000; 85(10): 3882 - 3891. [Abstract] [Full Text]

				C. C. Raggi, M. L. Bagnoni, G. P. Tonini, M. Maggi, G. Vona, P. Pinzani, K. Mazzocco, B. De Bernardi, M. Pazzagli, and C. Orlando Real-Time Quantitative PCR for the Measurement of MYCN Amplification in Human Neuroblastoma with the TaqMan Detection System Clin. Chem., November 1, 1999; 45(11): 1918 - 1924. [Abstract] [Full Text] [PDF]